| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms (NCT05455294) | Jacqueline Garcia, MD | 2022-07-18 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation (NCT05120570) | Masonic Cancer Center, University of Minnesota | 2022-03-17 |
| Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms (NCT05127174) | H. Lee Moffitt Cancer Center and Research Institute | 2022-03-14 |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (NCT05177211) | H. Lee Moffitt Cancer Center and Research Institute | 2022-03-01 |
| Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms (NCT04902833) | Massachusetts General Hospital | 2022-02-01 |
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) (NCT05524857) | Joseph Jurcic | 2022-01-28 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms (NCT05123365) | University of California, Irvine | 2022-01-03 |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant (NCT04898790) | University of Nebraska | 2021-11-18 |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms (NCT04955938) | University of Chicago | 2021-10-29 |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) (NCT04942080) | University Hospital, Angers | 2021-10-28 |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study (NCT05053100) | Mayo Clinic | 2021-08-17 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (NCT04279847) | Incyte Corporation | 2021-02-23 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (NCT04942730) | St. Petersburg State Pavlov Medical University | 2021-01-21 |
| Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (NCT04943757) | St. Petersburg State Pavlov Medical University | 2021-01-21 |
| Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm (NCT04744974) | University of California, Irvine | 2021-01-21 |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04493164) | M.D. Anderson Cancer Center | 2020-12-30 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms (NCT04637009) | Astex Pharmaceuticals, Inc. | 2020-12-21 |
| Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning (NCT04451200) | Institut Paoli-Calmettes | 2020-11-01 |
| Gastroesophageal Varices in Cavernoma (NCT04525768) | Shanghai Zhongshan Hospital | 2020-10-01 |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II (NCT03941769) | M.D. Anderson Cancer Center | 2020-09-29 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors (NCT04605211) | University of California, San Francisco | 2020-09-18 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations (NCT04493138) | M.D. Anderson Cancer Center | 2020-07-21 |
| Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). (NCT04378855) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-05-29 |
| COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias (NCT04416438) | French Innovative Leukemia Organisation | 2020-05-18 |
| Myeloproliferative Neoplasms (MPN) and COVID-19 (NCT04385160) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2020-05-13 |
| Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms (NCT04177576) | University Hospital, Bordeaux | 2020-02-24 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant (NCT03807063) | Fred Hutchinson Cancer Center | 2020-01-02 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients (NCT04103645) | Weill Medical College of Cornell University | 2019-11-22 |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm (NCT04041050) | AbbVie | 2019-11-08 |
| MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis (NCT04994158) | Royal Free Hospital NHS Foundation Trust | 2019-09-01 |
| Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms (NCT04192916) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2019-09-01 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (NCT03779854) | Fred Hutchinson Cancer Center | 2019-08-29 |
| Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results (NCT04060485) | National Taiwan University Hospital | 2019-08-19 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03862157) | M.D. Anderson Cancer Center | 2019-02-27 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms (NCT03878199) | Ohio State University Comprehensive Cancer Center | 2019-02-20 |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT03438344) | City of Hope Medical Center | 2018-12-01 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers (NCT03589729) | M.D. Anderson Cancer Center | 2018-09-19 |
| Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine (NCT03588078) | Groupe Francophone des Myelodysplasies | 2018-09-15 |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies (NCT03471260) | M.D. Anderson Cancer Center | 2018-03-19 |
| TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid (NCT03397173) | Case Comprehensive Cancer Center | 2018-03-16 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT03795779) | iCell Gene Therapeutics | 2018-03-01 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT04156256) | iCell Gene Therapeutics | 2018-03-01 |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN (NCT03386513) | AbbVie | 2018-01-02 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES (NCT06159816) | AUSL Romagna Rimini | 2017-11-01 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT03192397) | Roswell Park Cancer Institute | 2017-08-09 |
| Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors (NCT03238248) | Vanderbilt-Ingram Cancer Center | 2017-08-07 |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) (NCT02564536) | Washington University School of Medicine | 2017-06-01 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms (NCT03072043) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-18 |
| Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms (NCT06371573) | Federico II University | 2017-04-20 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02728050) | University of Washington | 2016-12-01 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (NCT02521493) | Children's Oncology Group | 2015-12-23 |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933) | City of Hope Medical Center | 2015-12-21 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02566304) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-13 |
| Project: Every Child for Younger Patients With Cancer (NCT02402244) | Children's Oncology Group | 2015-11-03 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT02396134) | City of Hope Medical Center | 2015-05-21 |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation (NCT02311569) | Swiss Cancer Institute | 2015-04-01 |
| Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis (NCT04631458) | Royal Free Hospital NHS Foundation Trust | 2014-11-12 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (NCT02121418) | University of Washington | 2014-06-01 |
| Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02029950) | National Cancer Institute (NCI) | 2013-12-16 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (NCT01822509) | National Cancer Institute (NCI) | 2013-05-16 |
| Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador (NCT05825326) | Sociedad de Lucha Contra el Cáncer del Ecuador | 2012-01-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1- (NCT02862366) | Lille Catholic University | 2010-10-01 |
| Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor (NCT01362985) | Genzyme, a Sanofi Company | 2009-07-01 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00397813) | Fred Hutchinson Cancer Center | 2006-01-01 |